Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

Pathogenesis of hyperinflation in chronic obstructive pulmonary disease

Authors Gagnon P, Guenette JA, Langer D, Laviolette L, Mainguy V, Maltais F, Ribeiro F, Saey D

Received 19 November 2013

Accepted for publication 30 December 2013

Published 15 February 2014 Volume 2014:9(1) Pages 187—201

DOI https://doi.org/10.2147/COPD.S38934

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Philippe Gagnon,1,2 Jordan A Guenette,3,4 Daniel Langer,5 Louis Laviolette,2 Vincent Mainguy,1 François Maltais,1,2 Fernanda Ribeiro,1,2 Didier Saey1,2

1Faculté de Médecine, Université Laval, 2Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, 3Centre for Heart Lung Innovation, University of British Columbia, St Paul's Hospital, 4Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada; 5Department of Kinesiology and Rehabilitation Sciences, KU Leuven, Leuven, Belgium

Abstract: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease characterized by airflow limitation that is not fully reversible. In a significant proportion of patients with COPD, reduced lung elastic recoil combined with expiratory flow limitation leads to lung hyperinflation during the course of the disease. Development of hyperinflation during the course of COPD is insidious. Dynamic hyperinflation is highly prevalent in the advanced stages of COPD, and new evidence suggests that it also occurs in many patients with mild disease, independently of the presence of resting hyperinflation. Hyperinflation is clinically relevant for patients with COPD mainly because it contributes to dyspnea, exercise intolerance, skeletal muscle limitations, morbidity, and reduced physical activity levels associated with the disease. Various pharmacological and nonpharmacological interventions have been shown to reduce hyperinflation and delay the onset of ventilatory limitation in patients with COPD. The aim of this review is to address the more recent literature regarding the pathogenesis, assessment, and management of both static and dynamic lung hyperinflation in patients with COPD. We also address the influence of biological sex and obesity and new developments in our understanding of hyperinflation in patients with mild COPD and its evolution during progression of the disease.

Keywords: chronic obstructive pulmonary disease, hyperinflation, expiratory flow limitation, operational lung volumes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Test-retest reliability of lower limb isokinetic endurance in COPD: a comparison of angular velocities

Ribeiro F, Lépine PA, Garceau-Bolduc C, Coats V, Allard E, Maltais F, Saey D

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1163-1172

Published Date: 18 June 2015

Readers of this article also read:

Antimicrobial activity of cream incorporated with silver nanoparticles biosynthesized from Withania somnifera

Marslin G, Selvakesavan RK, Franklin G, Sarmento B, Dias ACP

International Journal of Nanomedicine 2015, 10:5955-5963

Published Date: 22 September 2015

Physical inactivity and arterial stiffness in COPD

Sievi NA, Franzen D, Kohler M, Clarenbach CF

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1891-1897

Published Date: 10 September 2015

A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting

Wang SM, He X, Li N, Yu F, Hu Y, Wang LS, Zhang P, Du YK, Du SS, Yin ZF, Wei YR, Mulet X, Coia G, Weng D, He JH, Wu M, Li HP

International Journal of Nanomedicine 2015, 10:2857-2869

Published Date: 13 April 2015

How do COPD comorbidities affect ICU outcomes?

Ongel EA, Karakurt Z, Salturk C, Takir HB, Burunsuzoglu B, Kargin F, Ekinci GH, Mocin O, Gungor G, Adiguzel N, Yilmaz A

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1187-1196

Published Date: 17 October 2014

Central airways remodeling in COPD patients

Pini L, Pinelli V, Modina D, Bezzi M, Tiberio L, Tantucci C

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:927-933

Published Date: 1 September 2014

Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease

Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:715-721

Published Date: 9 July 2014

Multifunctional materials for bone cancer treatment

Marques C, Ferreira JMF, Andronescu E, Ficai D, Sonmez M, Ficai A

International Journal of Nanomedicine 2014, 9:2713-2725

Published Date: 28 May 2014

Effects of titania nanotubes with or without bovine serum albumin loaded on human gingival fibroblasts

Liu X, Zhou X, Li S, Lai R, Zhou Z, Zhang Y, Zhou L

International Journal of Nanomedicine 2014, 9:1185-1198

Published Date: 6 March 2014